


# Emerging Contaminants at Brownfields: The Role of Risk Communication


**Brownfields Summit 2022: Revitalizing New England**  
**May 18, 2022**

Stephen Zemba, PhD, PE (in MA)  
[szemba@sanbornhead.com](mailto:szemba@sanbornhead.com)




# Scope/Outline of Talk

- Risk Communication Background & Perspectives
- PFAS and PCBs Examples for Risk Communication



PFOA

PFBS



# The Devil We Know, Dark Waters, and a Roadmap



DONATE

WHY WE'RE HERE CAMPAIGNS RESULTS GET INVOLVED NEWS & EVENTS WHO WE ARE


BLOG PRESS RELEASES PRESS COVERAGE NEWSLETTERS EVENTS PODCASTS PUBLICATIONS

HOME »  
> BLOG »  
> ACTOR MARK RUFFALO, LEGENDARY ATTORNEY ROB BILOTT, AND CEH JOIN FORCES TO FIGHT THE PFAS CRISIS

SEPTEMBER 12, 2019

## Actor Mark Ruffalo, Legendary Attorney Rob Bilott, and CEH Join Forces to Fight the PFAS Crisis

BY RUBEN DIAZ




2018 The Devil We Know documentary promo (2:16)  
<https://www.youtube.com/watch?v=9GNAvYxalfM>

2021 PFAS Last Week Tonight with John Oliver (20 mins)  
<https://www.youtube.com/watch?v=9W74aeuqsiU>

## PFAS Action Plan February 14, 2019

### EPA's Per- and Polyfluoroalkyl Substances (PFAS) Action Plan



## Google Search Hits

- PFAS – 33,100,000
- Beatles – 192,000,000

NATIONAL  
LAW  
REVIEW

### Vermont Governor Signs Law Setting Strict PFAS Limits

Monday, May 20, 2019

### New Hampshire Adopts Aggressive PFAS Drinking Water Bill

Friday, July 24, 2020


### Massachusetts Finalizes Drinking Water Standard for PFAS

Monday, September 28, 2020



October 2021

### PFAS Strategic Roadmap: EPA's Commitments to Action 2021–2024



# EPA's PFAS Roadmap

Action	Legislation	Proposed/Final Rule	PFAS
Hazardous Substance Designations	CERCLA	Spring 2022/Summer 2023 <ul style="list-style-type: none"> <li>01/10/2022 proposed rule to OMB (90 days?)</li> <li>01/14/22 Federal Register notice seeking comment</li> </ul>	PFOS & PFOA
Ambient Water Quality Criteria	CWA	Winter 2022 (Aquatic Life) Fall 2024 (Human Health) <ul style="list-style-type: none"> <li>01/18/2022 Tribe Briefing</li> </ul>	PFOA & PFOS (benchmarks for other PFAS?)
NPDES Permits Effluent Limitation Guidelines	CWA	Winter 2022 <ul style="list-style-type: none"> <li>09/14/2021 advanced notice of rulemaking</li> </ul>	Up to 40 PFAS
Maximum Contaminant Levels	SDWA	Fall 2022/Fall 2023 <ul style="list-style-type: none"> <li>SAB meeting 12/16/2021 to 01/07/2022</li> </ul>	PFOS & PFOA
Health Advisories		Spring 2022 <ul style="list-style-type: none"> <li>01/18/2022 Tribe Briefing</li> </ul>	GenX & PFBS
Toxics Release Inventory	CAA	Spring 2022 (Enhanced) <ul style="list-style-type: none"> <li>01/24/2022 PFBS &amp; 3 additional compounds</li> </ul>	176 + 4 PFAS

- EPA's Lifetime Health Advisory of 70 ppt could be lowered ~10,000-fold based on preliminary interpretations of toxicity data
- EPA's Science Advisory Board (SAB) is also considering cancer risk in a similarly conservative manner

# Risk Communication - EPA's Perspective

## Embracing Risk Communication at EPA

Effectively communicating science and potential health risk is one of the most important jobs we have.

How effective are we at risk communication?

- **EPA's Definition:** Communication intended to supply audience members with the information they need to make informed, independent judgements about risks to health, safety, and the environment (1)
- **EPA's Goal:** To provide **meaningful, understandable, and actionable** information to our many audiences


<https://www.epa.gov/risk-communication/learn-about-risk-communication>

(1) Morgan, Fischhoff, Bostrom, Atman. Risk Communication: a Mental Models Approach


# Risk Communication

## Perspectives of a Risk Assessor & Engineer

- Risk communication guidance available (e.g., ITRC Toolkit)
- Personal Observations/Opinions
  - We are often not very good at communicating technical concepts
  - We have in some cases abandoned efforts to “talk science”
  - Use of sound bites and oversimplifications is not always useful
  - Process sometimes gets politicized



## The 4 Step Risk Assessment Process




# Risk Assessment Methods

- Origins of risk assessment go back to the 1980s (and earlier)
  - Used terms like “bounding estimates” and “overestimate”
  - Over time guidance standardized methods
- Health risk estimates are intentionally biased high
  - Cancer risks often based on the upper 95th percentile confidence limit of the slope of the dose-response curve
  - Non-cancer reference doses often incorporate multiplicative safety factors
- How are these concepts communicated?

# Relative Risk

## An Important Concept, But Slippery Slope

- Opinion: Important to emphasize the risk basis of regulatory programs and degree of protectiveness
- Risk of Death from COVID-19
  - ~ 1,000,000 in 330,000,000
  - = 1 in 330
  - =  $3 \times 10^{-3}$
- Superfund Acceptable Risk Range
  - 1 in 1,000,000 to 1 in 10,000
  - =  $1 \times 10^{-6}$  to  $1 \times 10^{-4}$
  - 30 to 3,000 times less than COVID-19
- Actuarial risks
  - Developing cancer: males 40.14%, females 38.70% -- 1 in 2.5
  - Dying from cancer: males 21.34%, females 18.33% -- 1 in 5






# What We Know about Health Effects (EPA 5/9/2022)

Current peer-reviewed scientific studies have shown that exposure to certain levels of PFAS may lead to:

- Reproductive effects such as decreased fertility or increased high blood pressure in pregnant women.
- Developmental effects or delays in children, including low birth weight, accelerated puberty, bone variations, or behavioral changes.
- Increased risk of some cancers, including prostate, kidney, and testicular cancers.
- Reduced ability of the body's immune system to fight infections, including reduced vaccine response.
- Interference with the body's natural hormones.
- Increased cholesterol levels and/or risk of obesity.



- Which PFAS?
- Points of departure?
- Dose-response data?
- Key studies?
- Animal studies v. human epi studies?
- Relevance of animal models?



# PFAS – A Class of Chemicals

Thousands of PFAS compounds have been identified

They have been used in countless applications thanks to unique and beneficial properties



## Fluorocarbon tail

- Strong bonds
- Hydrophobic
- Lipophobic
- Varying length
- Branched isomers


## Variations

- Chain length
- Fluorine saturation
- Precursors

## Functional group


- Strong to weak acids
- Hydrophilic
- Effects chemical properties

# PFOA Levels in Blood ( $\mu\text{g}/\text{L}$ )



- Exposure to PFOA and PFOS in water elevates levels in blood
- Bioconcentration over time  $\sim 100$ -fold


# PFOA Levels in Blood ( $\mu\text{g}/\text{L}$ )



**PFOS Levels in Blood**  
**National average: 4.3  $\mu\text{g}/\text{l}$**   
**Belmont MI individual: 3200  $\mu\text{g}/\text{l}$**

- PFOA background levels decreased from 5  $\mu\text{g}/\text{l}$  in late 1990s to present 2  $\mu\text{g}/\text{l}$
- PFOS background levels decreased from 31  $\mu\text{g}/\text{l}$  in late 1990s to present 4.3  $\mu\text{g}/\text{l}$


# NH Application of Multigenerational Model for PFOA




# Drinking Water Sampling (PA Data)

Peak Concentrations ↓, Frequency of Detection ↑

**Pennsylvania UCMR-3 PFOS + PFOA**  
Frequency of Detect = 29/1361



**2019 PA Phase I PFOS + PFOA**  
Frequency of Detect = 32/96




PA Phase 1 data: <http://files.dep.state.pa.us/Water/DrinkingWater/Perfluorinated%20Chemicals/SamplingResults/PFASPhase1ResultsSummary.pdf>

EPA UCMR3 data: <https://www.epa.gov/sites/production/files/2017-02/ucmr-3-occurrence-data.zip>

# Risk-Based Standards


- Regulators are making different assumptions and interpretations in the face of uncertainty
- Results: Substantial variability and in some cases adoption of very protective assumptions



Regulatory Authority	Receptor	Chemical	Reference Dose (ng/kg-d)	Background Exemption	Exposure Rate (l/kg-d)	Risk-Based Concentration (ng/l = ppt)
U.S. EPA LHA	Nursing mother	PFOA + PFOS	20	80%	0.054	70
VT DOH	Nursing infant	PFOA + PFOS	20	80%	0.175	20
TX CEQ	Small child	PFOA	12	0%	0.041	290
		PFOS	23			560

# Likelihood of Finding PFAS in Groundwater Near Sites is High

NH PFAS Sampling  
Frequency of Detections



**STATUS REPORT ON THE OCCURRENCE OF PER- AND POLYFLUOROALKYL SUBSTANCES (PFAS) CONTAMINATION IN NEW HAMPSHIRE**

*This report has been developed to satisfy the requirements of the Laws of New Hampshire  
January Session of 2018, Chapter 306:2 (HB 1766)*

Prepared by  
New Hampshire Department of Environmental Services

Robert R. Scott, Commissioner

June 2021




PO Box 95, Concord, NH 03302-0095  
[www.des.nh.gov](http://www.des.nh.gov)


Some sampling bias toward expected sites, but also many surprises



# Also Likely to Find PFAS in Soil – VT Background Levels



- >5,000  
8 locations
  - 2,000-5,000  
23 locations
  - 1,000-2,000  
25 locations
  - <1,000  
10 locations
- $\Sigma$ PFAS (ng/kg)




- Median PFOA = 370 ppt (ng/kg)
- Median PFOS = 680 ppt (ng/kg)

# Also Likely to Find PFAS in Surface Water

## Colorado DPHE 2020 PFAS Sampling Effort


PFAS Concentrations in Colorado Streams  
(number of locations= 43)



- 18 PFAS investigated
- At least one PFAS detected in every sample


# PFAS Issues and Concerns at Brownfield Sites

- Risk perception by stakeholders
- Groundwater typically riskier than soil
  - Drinking water dominates exposure
  - BUT soil can be a source to groundwater
- Institutional controls can restrict exposure on-site
  - Soil disposal options increasing in cost
- Some PFAS are “forever” chemicals – liability?
  - Insurance may cover PFAS, may increase cost
- Phase 1 due diligence – to sample, or not to sample?
  - Requirements ambiguous – regulations are likely
  - PFAS background levels exist in soil – detection likely
  - PFAS is found in groundwater at many types of sites
  - Sources can be off-site – including air deposition impacts




# PCB Toxicological Values for Risk Assessment

- Carcinogenic Potencies (kg-day/mg) (EPA IRIS, 1996)
  - High risk/persistence 1 to 2
  - Low risk/persistence 0.3 to 0.4
  - Lowest risk/persistence 0.04 to 0.07
  - 2,3,7,8-TCDD 130,000 (TEQ/co-planar)



- “Non-cancer” Reference Doses (ng/kg-day) (EPA IRIS, 1994 for Aroclors)
  - Aroclor 1254 20 higher risk
  - Aroclor 1016 70 lower risk
  - 2,3,7,8-TCDD 0.0007 TEQ/co-planar



- Neurological Equivalent Reference Doses (ng/kg-day) (Simon, 2007)
  - Aroclor 1254 8 higher risk
  - Aroclor 1016 70 lower risk

# Indoor Air Screening Levels

## EPA's Exposure Levels for Evaluating Polychlorinated Biphenyls (PCBs) in Indoor School Air (ng/m<sup>3</sup>)

(<https://www.epa.gov/pcbs/exposure-levels-evaluating-polychlorinated-biphenyls-pcbs-indoor-school-air>)


Age 1-<2	Age 2-<3	Age 3-<6	Age 6-<12	Age 12-<15	Age 15-<19	Age 19+
100	100	200	300	500	600	500

## EPA's Regional Screening Levels (ng/m<sup>3</sup>)

(<https://www.epa.gov/risk/regional-screening-levels-rsls-generic-tables>, TR=1E-06)

	High Risk (dust)	Low Risk (evaporated)	Lowest Risk (99.5% <4 Cl)
Residential	4.9	28	140
Industrial	21	120	610


# Aroclor 1016



PCB Congener	2,3,7,8-TCDD TEF
77	0.0001
81	0.0003
105	0.00003
114	0.00003
118	0.00003
123	0.00003
126	0.1
156	0.00003
157	0.00003
167	0.00003
169	0.03
170	0
180	0
189	0.00003

Composition data from ATSDR (2000) Toxicity Profile for PCBs

# Aroclor 1254



PCB Congener	2,3,7,8-TCDD TEF
77	0.0001
81	0.0003
105	0.00003
114	0.00003
118	0.00003
123	0.00003
126	0.1
156	0.00003
157	0.00003
167	0.00003
169	0.03
170	0
180	0
189	0.00003

Composition data from ATSDR (2000) Toxicity Profile for PCBs



# Summary

- Science can be complex
- Uncertainties in risk assessments are substantial
- If the goal of risk communication is to provide “meaningful, understandable, and actionable information”
  - Talk more deeply about science
  - Discuss uncertainties from multiple angles
  - Explain rationales for protection of public health



# Thank you for your attention!

## Questions ?



Also please write or call with any off-line questions



Stephen Zemba, PhD, PE (in MA)  
 Project Director  
 szemba@sanbornhead.com  
 T 802.391.8508